Josep M. Llovet, MD, PhD, discussed the available treatment options for patients with hepatocellular carcinoma.
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the available treatment options for patients with hepatocellular carcinoma (HCC).
The standard of care for early-stage HCC, which makes up about 40% of patients, is resection, transplant, or local ablation, says Llovet. For intermediate-stage disease, the standard is chemoembolization. For the 40% of patients with advanced disease, frontline sorafenib (Nexavar) has been the standard of care for almost 12 years.